

N.Pinkhover¹, E.Sanchez¹, K.Pontbriand¹, J.Auclair¹, M.Gandhi², S.Vishnubhotla², T.Proctor²
 1 Life Science Testing Center, Northeastern University, Burlington, MA, USA
 2 Thermo Fisher Scientific, South San Francisco, CA, USA

Introduction

As Covid-19 vaccination rates remain unsatisfactory, the exponential spread of SARS-CoV-2 variants of concern continue to pose a threat to global public health. Surveillance testing is critical for tracking viral progression, vaccine breakthrough, and emerging SARS-CoV-2 variants as the pandemic continues to evolve. While whole genome sequencing (WGS) is the primary method used for genomic surveillance; it is a costly and resource intensive process for population scale implementation. In this study, we describe an alternative, lower-cost quick PCR-based method for the detection and discrimination of 4 currently designated VOCs; alpha (B.1.1.7), beta (B.1.351), gamma (P.1), and delta (B.1.617).

Experimental Methodology

The study included 108 SARS-CoV-2 positive specimens received at the Life Science Testing Center at Northeastern University between April to August 2021. RNA was extracted using MagMax™ Viral/Pathogen II Nucleic Acid Isolation Kit automated on Agilent™ Bravo Liquid Handlers and SARS-CoV-2 status was determined using TaqPath™ COVID-19 Combo Kit. Variant profiling was performed on extracted RNA using a panel of TaqMan SARS-CoV-2 genotyping assays. 5.0µL of sample RNA or Thermo Scientific™ Acrometrix™ Coronavirus 2019 (COVID-19) RNA Control was then aliquoted into 96-well optical plates containing TaqMan™ SARS-CoV-2 variant-specific assay mix (15µL) as shown in Table 1.

Component	Volume per assay	Volume per 96-well plate
TaqPath™ 1-Step RT-qPCR Master Mix, CG (4X)	5 µL	528 µL
TaqMan™ SARS-CoV-2 Mutation Panel Assay (40X)	0.5 µL	52.8 µL
Nuclease-free Water	9.5 µL	1003.2 µL
Total Reaction Mix Volume	15 µL	1584 µL

Table 1: Volumes of each component for 96-well plate TaqMan™ SARS-CoV-2 Mutation Panel Setup

Both a 12 and 8 assay panel were tested using the following assays: N439K, K417T, D215G, delH69V/70, E484K, T20N, P681R, L452R, N501Y, E484Q, Q27STOP, A222V. The 8-assay panel excluded the N501Y, E484Q, Q27STOP, and A222V assays. 44 samples were run using the 8-assay panel and 64 using the 12-assay panel. Layout of 8 samples on the 96-well optical plate for the 12-assay panel is illustrated in Figure 1

	N439K	K417T	D215G	delH69V70	E484K	T20N	P681R	L452R	N501Y	E484Q	Q27Stop	A222V
A Sample 1												
B Sample 2												
C Sample 3												
D Sample 4												
E Sample 5												
F Sample 6												
G Sample 7												
H Sample 8												

Figure 1: 96-well optical plate layout

The SARS-CoV-2 lineages were assigned using a classifier based on the MOC combination (Table 2). Initial mutant results and variant classification were verified by Next Generation Sequencing using Thermo Fisher Scientific's Ion Torrent- GeneStudio-S5 Plus System. Lineages were assigned based on the MOC Data analysis was performed using Applied Biosystems™ Design and Analysis Software Version 2.5.1, via allelic discrimination scatter plots for variant genotyping determination. Further statistical analyses and graphical data representations were performed using JMP® Pro 15.0.0.

SARS-CoV-2 Lineage	N439K	K417T	D215G	delH69V70	E484K	T20N	P681R	L452R	N501Y	E484Q	Q27STOP	A222V
Alpha (B.1.1.7)	Y			Y					Y		Y	
Beta (B.1.351)			Y		Y				Y			
Gamma (P.1)		Y			Y	Y			Y			
Delta (B.1.617.2)							Y	Y				

Table 2. 12 MOC-panel for VOC discrimination. Note: E484Q (B.1.617.1 and B.1.617.3) and A222V (B.1.177) were included in the panel to cover other variants

Results

Of the 108 samples, 25 samples were classified as Alpha variant, 1 as Beta, 7 as Gamma, and 48 as Delta. SARS-CoV-2 lineages were unable to assigned for 27 samples (Figure 2)




Figure 2. Frequency of SARS-CoV-2 lineages in screened positive patient samples at Northeastern University from April to August 2021 using PCR-based MOC panel

The MOC-panel is nearly 4X cheaper than sequencing with a per sample cost of \$20.50 for 96-samples (MOC panel) as compared to \$81.39 (NGS) (Fig. 4)




Figure 4. Cost benefit analysis between NGS and MOC panel for VOC surveillance testing

Results (con't)

12-Assay MOC Panel confirmation of B.1.617.2 (Delta-specific) P681R SARS-CoV-2 mutation in 8 samples collected from NU population is shown in Figure 3.




Figure 3. Eight (8) confirmed Delta variants displaying full amplification of the Proline681Arginine (P681R) spike glycoprotein mutation using the 12-assay mutant panel. Samples expressing VIC-labeled mutant alleles (blue) amplify linearly in the y-axis.

12-Assay MOC Panel confirming absence of B.1.258 (multi-variant) N439K SARS-CoV-2 Mutation in 8 Samples Collected from NU Population. Column-4 and Column-11 displaying WT/reference amplification for 2 B.1.1.7 (Alpha-specific) del.H69V70 and Q27STOP SNPs across the same 8 NU samples seen in Figure 4.




Figure 4. The same eight (8) samples from figure 2 displaying reference allele (WT) amplification of the Asparagine439Lysine (N439K) of the spike glycoprotein. Samples expressing WT alleles (FAM-labeled) clustered linearly along the x-axis.

- The 8-assay panel identified variant class with a mean of 45.50% (n=20/44, p= .05),
- The 12-assay layout identified variant class with a mean of 95.31% (61/64, p= .05).
- Used in combination, the 8-assay and 12-assay MOC panels conclusively identified four (4) current VOCs (Alpha, Beta, Delta, Gamma) with a mean of 75.0% (n=81/104, p= .05) of previously confirmed positive COVID-19 samples.

- Despite a negligible cost difference between layouts (the 8-assay's slight cost advantage), the 12-assay layout showed a substantial increase in mean analytical performance.

- Comparison of the two plate layouts revealed the 12-assay layout was superior in performance by a factor >2.

- These data indicate our optimized 12-assay layout using the TaqMan™ SARS-CoV-2 Mutation Panel provides a significantly reliable, robust, and highly scalable method for surveillance of SARS-CoV-2 Variants of Concern.

Conclusions/Discussion

SNP-PCR panels offer an easily implemented, cost-effective and robust method for at-scale surveillance of SARS-CoV-2 Variants of Concern. Optimizing 96-well MOC panels is critical for achieving high VOC classification and cost-benefit for large-scale surveillance. MOC panels afford efficient workflows and fast turn-around-times, which is crucial in monitoring the evolution COVID-19 pandemic.